Combination treatment of dilated cardiomyopathy

Abstract

Treatment of dilated cardiomyopathy in a subject by combination treatment with a tyrosine kinase inhibitor and a statin.

What is claimed is: 
     
         1 . A method of treating dilated cardiomyopathy in a subject, comprising concomitant administration to the subject of a therapeutically effective amount of:
 (a) a tyrosine kinase inhibitor; and   (b) a statin.   
     
     
         2 . The method of  claim 1  where the tyrosine kinase inhibitor is axitinib, cediranib, crenolanib, dasatinib, imatinib, linifenib, motesanib, nilotinib, pazopanib, ponatinib, quizartinib, sorafenib, or sunitinib. 
     
     
         3 . The method of  claim 1  or  2  where the statin is atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin. 
     
     
         4 . The method of  claim 1  where the subject has a mutation in either or both of the subject's lamin A and filamin C proteins. 
     
     
         5 . The method of  claim 4  where the subject has a mutation in the subject's lamin A protein. 
     
     
         6 . The method of  claim 4  where the subject has a mutation in the subject's filamin C protein. 
     
     
         7 . The method of  claim 4  where the subject has a mutation in both the subject's lamin A and filamin C proteins. 
     
     
         8 . The method of  claim 4  where the mutation in the subject's lamin A protein is one or more of Q6*, R26G, K32del, A57P, L59R, R60G, E82K, L85R, K117fs, R133P, L140R, E145K, E161K, N195K, E203G, H222P, R225Q, R249Q, Y267C, R298C, D300G, E358K, M371K, R377H, R453W, R527P, T528R, L530P, R541G, R571S, S573L, V607V, G608S, G608G, and Q656Q. 
     
     
         9 . The method of  claim 4  where the mutation in the subject's filamin C protein is one or more of Y83*, F106L, R991*, P963R, A1183L, A1186V, V1198Gfs*64, S1642L, G1891Vfs61X, G2011E, 12160F, E2189X, V2297M, P2298L, G2299S, R2318W, R2410C, and Y2563C. 
     
     
         10 . The method of  claim 1  where the subject is tested for the presence of a mutation in the subject's LMNA or FLNC gene, or lamin A or filamin C protein, before treatment. 
     
     
         11 . The method of  claim 2  where the subject has a mutation in either or both of the subject's lamin A and filamin C proteins. 
     
     
         12 . The method of  claim 3  where the subject has a mutation in either or both of the subject's lamin A and filamin C proteins. 
     
     
         13 . The method of  claim 2  where the subject is tested for the presence of a mutation in the subject's LMNA or FLNC gene, or lamin A or filamin C protein, before treatment. 
     
     
         14 . The method of  claim 3  where the subject is tested for the presence of a mutation in the subject's LMNA or FLNC gene, or lamin A or filamin C protein, before treatment.